Does the media prefer KURA or AVXL?

In the previous week, Kura Oncology had 5 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Kura Oncology and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Kura Oncology's score of -0.62 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SDGR or AVXL?

In the previous week, Schrodinger had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Anavex Life Sciences. Schrodinger's average media sentiment score of 1.15 beat Anavex Life Sciences' score of 0.93 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ETON or AVXL?

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Anavex Life Sciences. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Eton Pharmaceuticals' score of 0.20 indicating that Anavex Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AVXL or PHAR?

In the previous week, Pharming Group had 5 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Pharming Group and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Pharming Group's score of 0.27 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Anavex Life Sciences (AVXL) Competitors

$2.64 -0.15 (-5.38%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$2.66 +0.02 (+0.76%)

As of 04:00 AM Eastern

Compare

AVXL vs. KURA, SDGR, PHAT, ETON, and PHAR

Should you buy Anavex Life Sciences stock or one of its competitors? MarketBeat compares Anavex Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anavex Life Sciences include Kura Oncology (KURA), Schrodinger (SDGR), Phathom Pharmaceuticals (PHAT), Eton Pharmaceuticals (ETON), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry.

How does Anavex Life Sciences compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Anavex Life Sciences has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Anavex Life Sciences' return on equity of -38.76% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-411.19%	-141.95%	-43.28%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Kura Oncology has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

31.6% of Anavex Life Sciences shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Anavex Life Sciences has lower revenue, but higher earnings than Kura Oncology. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	11.39	-$278.67M	-$3.35	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

In the previous week, Kura Oncology had 5 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Kura Oncology and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Kura Oncology's score of -0.62 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology presently has a consensus price target of $25.90, indicating a potential upside of 199.25%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 708.08%. Given Anavex Life Sciences' higher possible upside, analysts clearly believe Anavex Life Sciences is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Anavex Life Sciences beats Kura Oncology on 10 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Schrodinger?

Schrodinger (NASDAQ:SDGR) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Anavex Life Sciences has a net margin of 0.00% compared to Schrodinger's net margin of -40.61%. Schrodinger's return on equity of -30.85% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrodinger	-40.61%	-30.85%	-15.32%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Anavex Life Sciences has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrodinger	$255.87M	4.31	-$103.26M	-$1.41	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

In the previous week, Schrodinger had 1 more articles in the media than Anavex Life Sciences. MarketBeat recorded 3 mentions for Schrodinger and 2 mentions for Anavex Life Sciences. Schrodinger's average media sentiment score of 1.15 beat Anavex Life Sciences' score of 0.93 indicating that Schrodinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrodinger	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Schrodinger currently has a consensus target price of $20.25, indicating a potential upside of 35.63%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 708.08%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrodinger	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

79.1% of Schrodinger shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Schrodinger has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Summary

Schrodinger beats Anavex Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, media sentiment, analyst recommendations and risk.

In the previous week, Anavex Life Sciences had 1 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 2 mentions for Anavex Life Sciences and 1 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.87 beat Anavex Life Sciences' score of 0.93 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Very Positive
Anavex Life Sciences	Positive

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Anavex Life Sciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Anavex Life Sciences	N/A	-38.76%	-35.01%

Phathom Pharmaceuticals presently has a consensus price target of $25.00, indicating a potential upside of 147.77%. Anavex Life Sciences has a consensus price target of $21.33, indicating a potential upside of 708.08%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences has lower revenue, but higher earnings than Phathom Pharmaceuticals. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.60	-$221.25M	-$2.12	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Phathom Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Summary

Phathom Pharmaceuticals and Anavex Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Anavex Life Sciences compare to Eton Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

Eton Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 48.50%. Anavex Life Sciences has a consensus price target of $21.33, suggesting a potential upside of 708.08%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eton Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Anavex Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	9.46	-$4.60M	-$0.07	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A

Anavex Life Sciences has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Anavex Life Sciences	N/A	-38.76%	-35.01%

In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Anavex Life Sciences. MarketBeat recorded 6 mentions for Eton Pharmaceuticals and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Eton Pharmaceuticals' score of 0.20 indicating that Anavex Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Summary

Eton Pharmaceuticals beats Anavex Life Sciences on 7 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Pharming Group?

Anavex Life Sciences (NASDAQ:AVXL) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

31.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Pharming Group had 5 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Pharming Group and 2 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 0.93 beat Pharming Group's score of 0.27 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 708.08%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 213.18%. Given Anavex Life Sciences' higher probable upside, research analysts clearly believe Anavex Life Sciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
Pharming Group	$376.13M	2.30	$2.85M	$0.16	76.50

Pharming Group has a net margin of 3.30% compared to Anavex Life Sciences' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
Pharming Group	3.30%	4.64%	2.55%

Summary

Pharming Group beats Anavex Life Sciences on 8 of the 13 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$258.09M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	-5.74	17.78	22.17	24.18
Price / Sales	N/A	315.63	523.06	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	2.40	6.63	9.79	6.72
Net Income	-$46.38M	$24.20M	$3.57B	$337.19M
7 Day Performance	-10.20%	-4.39%	-2.49%	-0.75%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	-65.80%	45.50%	26.49%	33.09%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	2.0045 of 5 stars	$2.64 -5.4%	$21.33 +708.1%	-66.3%	$258.09M	N/A	N/A	40	Upcoming Earnings Gap Down
KURA Kura Oncology	2.1873 of 5 stars	$11.25 flat	$26.38 +134.4%	+34.8%	$998.71M	$67.48M	N/A	130	News Coverage
SDGR Schrodinger	3.2256 of 5 stars	$13.30 flat	$20.25 +52.3%	-34.8%	$981.87M	$255.87M	N/A	790	Positive News Gap Down
PHAT Phathom Pharmaceuticals	2.6988 of 5 stars	$11.33 flat	$25.00 +120.7%	+103.8%	$903.64M	$175.11M	N/A	110	Positive News
ETON Eton Pharmaceuticals	4.4236 of 5 stars	$32.59 flat	$41.00 +25.8%	+59.8%	$892.71M	$79.95M	N/A	20	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. KURA, SDGR, PHAT, ETON, and PHAR

How does Anavex Life Sciences compare to Kura Oncology?

Summary

How does Anavex Life Sciences compare to Schrodinger?

Summary

How does Anavex Life Sciences compare to Phathom Pharmaceuticals?

Summary

How does Anavex Life Sciences compare to Eton Pharmaceuticals?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. KURA, SDGR, PHAT, ETON, and PHAR

How does Anavex Life Sciences compare to Kura Oncology?

Is KURA or AVXL more profitable?

Which has more volatility & risk, KURA or AVXL?

Do insiders and institutionals have more ownership in KURA or AVXL?

Which has higher earnings and valuation, KURA or AVXL?

Does the media prefer KURA or AVXL?

Do analysts rate KURA or AVXL?

Summary

How does Anavex Life Sciences compare to Schrodinger?

Is SDGR or AVXL more profitable?

Which has higher valuation & earnings, SDGR or AVXL?

Does the media prefer SDGR or AVXL?

Do analysts prefer SDGR or AVXL?

Do institutionals & insiders believe in SDGR or AVXL?

Which has more volatility & risk, SDGR or AVXL?

Summary

How does Anavex Life Sciences compare to Phathom Pharmaceuticals?

Does the media prefer PHAT or AVXL?

Do institutionals and insiders believe in PHAT or AVXL?

Is PHAT or AVXL more profitable?

Do analysts prefer PHAT or AVXL?

Which has preferable earnings and valuation, PHAT or AVXL?

Which has more risk and volatility, PHAT or AVXL?

Summary

How does Anavex Life Sciences compare to Eton Pharmaceuticals?

Do analysts recommend ETON or AVXL?

Do institutionals & insiders hold more shares of ETON or AVXL?

Which has stronger valuation and earnings, ETON or AVXL?

Is ETON or AVXL more profitable?

Does the media refer more to ETON or AVXL?

Which has more risk and volatility, ETON or AVXL?

Summary

How does Anavex Life Sciences compare to Pharming Group?

Do insiders & institutionals hold more shares of AVXL or PHAR?

Does the media refer more to AVXL or PHAR?

Which has more risk and volatility, AVXL or PHAR?

Do analysts recommend AVXL or PHAR?

Which has better earnings & valuation, AVXL or PHAR?

Is AVXL or PHAR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools